An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combination With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Japanese Participants With Advanced Non-small Cell Lung Cancer - ICH GCP - Clinical Trials Registry